Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study to evaluate the dosage, safety and efficacy of inhaled Cannabidiol

Next Previous
X
Search
Trial Profile

A clinical study to evaluate the dosage, safety and efficacy of inhaled Cannabidiol

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Anxiety; Arthritis; Attention-deficit hyperactivity disorder; Depression; Insomnia; Pain
  • Focus Adverse reactions

    • Most Recent Events

    • 09 Jun 2021 New trial record
    • 02 Jun 2021 According to a Rapid Therapeutic Science Laboratories media release, the company has engaged Dr. Charles Powell, MD, (CMO, Founder) of a primary care group in North Texas with over 90,000 patients from which volunteers will be solicited for the planned studies. Dr. Powell will work in conjugation with Dr. Haresh Boghara, MD of Epic Medical Research (RTSL's primary medical investigator).
    • 02 Jun 2021 According to a Rapid Therapeutic Science Laboratories media release, IND filing for metered dose inhaler (MDI) containing Cannabidiol (CBD) is expected in the next 30 days.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top